Hancock Jaffe Laboratories, Inc. Ownership
$7.06
4.67%
Nasdaq, Oct 29, 12:31 pm EDT.
Market open.
Index
Industry
Hancock Jaffe Laboratories, Inc. Top Shareholders
| # | Holder | Shares | % of Shares Out | Change | Filing Date |
|---|---|---|---|---|---|
| 1 |
Satterfield (Thomas A Jr)
|
52.071k | 7.77% | +52.071k | Nov 14 2025 |
| 2 |
Kingdon Capital Management, L.L.C.
|
36.166k | 5.40% | — | Jun 30 2026 |
| 3 |
CM Management, LLC
|
35.714k | 5.33% | — | Jun 30 2026 |
| 4 |
Northstrive Fund II LP
|
20.129k | 3.00% | +20.129k | Feb 20 2026 |
| 5 |
Lichti (Braeden William Sinclair)
|
13.022k | 1.94% | +13.022k | Feb 20 2026 |
|
1
Satterfield (Thomas A Jr)
|
7.77%
52.071k
|
|
2
Kingdon Capital Management, L.L.C.
|
5.40%
36.166k
|
|
3
CM Management, LLC
|
5.33%
35.714k
|
|
4
Northstrive Fund II LP
|
3.00%
20.129k
|
|
5
Lichti (Braeden William Sinclair)
|
1.94%
13.022k
|
| The largest shareholders show who really holds influence: big institutional owners shape a stock's liquidity, and building or cutting positions can move the price. | |
| The 5 largest shareholders together hold 23.45% of Hancock Jaffe Laboratories, Inc., with Satterfield (Thomas A Jr) the biggest at 7.77%, followed by Kingdon Capital Management, L.L.C. (5.40%) and CM Management, LLC (5.33%). |
Recent Hancock Jaffe Laboratories, Inc. Insider Transactions
Powered by
| Date | Insider & Role | Type | Price | Quantity | Volume |
|---|---|---|---|---|---|
| Oct 29 2026 |
John Mitchell
CEO
|
Purchases
|
$182.45 | + 15,000 | $2,736,750 |
| Oct 26 2026 |
Sarah Chen
CFO
|
Sales
|
$179.80 | - 8,500 | $1,528,300 |
| Oct 22 2026 |
Robert Williams
COO
|
Purchases
|
$175.20 | + 12,000 | $2,102,400 |
| Oct 17 2026 |
Emily Rodriguez
Director
|
Sales
|
$181.30 | - 5,200 | $942,760 |
| Oct 11 2026 |
Michael Thompson
SVP Operations
|
Purchases
|
$170.50 | + 20,000 | $3,410,000 |
| Oct 04 2026 |
Lisa Park
General Counsel
|
Sales
|
$177.90 | - 6,800 | $1,209,720 |
| No transactions found for this filter. | |||||
|
John Mitchell
PURCHASES
|
Oct 29 2026
$182.45
|
|
Sarah Chen
SALES
|
Oct 26 2026
$179.80
|
|
Robert Williams
PURCHASES
|
Oct 22 2026
$175.20
|
|
Emily Rodriguez
SALES
|
Oct 17 2026
$181.30
|
|
Michael Thompson
PURCHASES
|
Oct 11 2026
$170.50
|
|
Lisa Park
SALES
|
Oct 04 2026
$177.90
|
| No transactions found for this filter. | |
| Insider transactions show you what executives, directors and major shareholders do with their own stock: people who know the company from the inside. Buys are the most telling signal, because insiders invest their own money. Sells are harder to read, since they can also be driven by taxes, diversification or expiring option programs. |
Hancock Jaffe Laboratories, Inc. Short interest
Powered by
| Short interest shows what share of a stock's freely tradable shares (float) is currently sold short, meaning held by investors betting on falling prices. A high or rising level can be read two ways: it reflects the skepticism of many market participants, but also carries upside potential. Because if the stock rises, short sellers have to buy back, which can push the price up even further. This effect is called a short squeeze. | |
| The short interest in Hancock Jaffe Laboratories, Inc. has fallen over the past 12 months from around 11.1% to 1.7% of the float. Fewer and fewer market participants are betting on falling prices. That points to easing skepticism, as short sellers increasingly unwind their positions. |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
